GlaxoSmithKline Operating Income from 2010 to 2026

GSK Stock

USD 53.34 0.87 1.66%

GlaxoSmithKline PLC Operating Income yearly trend continues to be quite stable with very little volatility. Operating Income may rise above about 4.7 B this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit GlaxoSmithKline PLC ADR generates from its operations. View All Fundamentals

Operating Income

First Reported

1985-09-30

Previous Quarter

2 B

Current Value

2.6 B

Quarterly Volatility

1.5 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 B, Interest Expense of 495.6 M or Total Revenue of 19.8 B, as well as many indicators such as Price To Sales Ratio of 1.91, Dividend Yield of 0.0394 or PTB Ratio of 4.39. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.

Build AI portfolio with GlaxoSmithKline Stock

Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

Historical Operating Income data for GlaxoSmithKline PLC serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether GlaxoSmithKline PLC ADR represents a compelling investment opportunity.

Latest GlaxoSmithKline PLC's Operating Income Growth Pattern

Below is the plot of the Operating Income of GlaxoSmithKline PLC ADR over the last few years. Operating Income is the amount of profit realized from GlaxoSmithKline PLC ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of GlaxoSmithKline PLC ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. GlaxoSmithKline PLC's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Operating Income

Timeline

GlaxoSmithKline Operating Income Regression Statistics

	Arithmetic Mean	5,452,852,656
	Geometric Mean	4,792,710,299
	Coefficient Of Variation	41.42
	Mean Deviation	1,762,626,599
	Median	5,483,000,000
	Standard Deviation	2,258,346,765
	Sample Variance	5100130.1T
	Range	9.7B
	R-Value	(0.04)
	Mean Square Error	5431342.3T
	R-Squared	0
	Significance	0.88
	Slope	(17,983,306)
	Total Sum of Squares	81602081.8T

GlaxoSmithKline Operating Income History

	2026	4.7 B
	2025	4.6 B
	2024	4 B
	2023	6.7 B
	2022	6.4 B
	2021	4.4 B
	2020	6 B

Other Fundumenentals of GlaxoSmithKline PLC ADR

Non Operating Income Net Other

GlaxoSmithKline PLC Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Intangible Assets	Retained Earnings	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Treasury Stock	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Cash And Equivalents
Total Assets		0.69	0.93	0.2	0.95	0.04	0.98	0.95	0.55	0.75	0.89	0.96	0.5	0.43	0.98	-0.2	0.2	0.21	-0.18	0.62	-0.51	0.68	0.41	0.58	0.66	-0.01
Total Stockholder Equity	0.69		0.58	-0.35	0.73	0.15	0.57	0.69	0.34	0.36	0.69	0.63	0.94	0.26	0.78	-0.31	0.13	0.19	0.08	0.79	-0.39	0.62	0.71	0.51	0.8	-0.51
Net Debt	0.93	0.58		0.09	0.89	0.04	0.93	0.89	0.5	0.91	0.83	0.91	0.4	0.57	0.9	-0.02	0.16	0.12	-0.07	0.51	-0.41	0.77	0.28	0.63	0.63	0.11
Accounts Payable	0.2	-0.35	0.09		0.13	-0.15	0.31	0.16	0.28	0.06	0.19	0.21	-0.53	-0.03	0.1	-0.09	0.14	0.25	-0.33	0.0	-0.43	-0.19	-0.15	-0.14	-0.26	0.21
Net Receivables	0.95	0.73	0.89	0.13		0.13	0.93	0.95	0.6	0.73	0.93	0.87	0.53	0.46	0.93	-0.11	0.19	0.08	0.03	0.63	-0.47	0.59	0.46	0.53	0.68	-0.15
Short Term Investments	0.04	0.15	0.04	-0.15	0.13		0.04	0.2	-0.02	0.01	0.03	-0.09	0.15	-0.2	0.03	-0.3	0.17	0.18	0.16	0.28	-0.15	-0.12	0.27	-0.18	0.49	-0.2
Total Liab	0.98	0.57	0.93	0.31	0.93	0.04		0.95	0.6	0.78	0.89	0.94	0.35	0.43	0.93	-0.19	0.23	0.22	-0.21	0.58	-0.56	0.63	0.37	0.56	0.61	0.03
Total Current Assets	0.95	0.69	0.89	0.16	0.95	0.2	0.95		0.69	0.71	0.95	0.85	0.46	0.52	0.9	-0.13	0.05	0.2	-0.15	0.6	-0.51	0.57	0.43	0.52	0.68	-0.09
Capital Stock	0.55	0.34	0.5	0.28	0.6	-0.02	0.6	0.69		0.42	0.81	0.36	0.02	0.66	0.44	0.14	-0.32	0.07	-0.12	0.32	-0.43	0.12	0.34	0.18	0.26	-0.17
Short Term Debt	0.75	0.36	0.91	0.06	0.73	0.01	0.78	0.71	0.42		0.67	0.75	0.21	0.55	0.73	0.09	0.2	-0.07	0.06	0.36	-0.24	0.73	0.14	0.58	0.47	0.2
Common Stock	0.89	0.69	0.83	0.19	0.93	0.03	0.89	0.95	0.81	0.67		0.78	0.42	0.64	0.84	0.02	-0.1	0.13	-0.12	0.55	-0.48	0.51	0.4	0.47	0.55	-0.17
Intangible Assets	0.96	0.63	0.91	0.21	0.87	-0.09	0.94	0.85	0.36	0.75	0.78		0.49	0.35	0.97	-0.22	0.28	0.19	-0.24	0.57	-0.44	0.77	0.31	0.58	0.57	0.1
Retained Earnings	0.5	0.94	0.4	-0.53	0.53	0.15	0.35	0.46	0.02	0.21	0.42	0.49		0.04	0.64	-0.34	0.21	0.12	0.17	0.7	-0.19	0.57	0.64	0.45	0.73	-0.47
Long Term Debt	0.43	0.26	0.57	-0.03	0.46	-0.2	0.43	0.52	0.66	0.55	0.64	0.35	0.04		0.38	0.65	-0.55	-0.22	0.07	-0.04	0.01	0.4	-0.12	0.18	0.08	0.26
Good Will	0.98	0.78	0.9	0.1	0.93	0.03	0.93	0.9	0.44	0.73	0.84	0.97	0.64	0.38		-0.26	0.27	0.2	-0.12	0.71	-0.5	0.77	0.48	0.6	0.71	-0.07
Property Plant Equipment	-0.2	-0.31	-0.02	-0.09	-0.11	-0.3	-0.19	-0.13	0.14	0.09	0.02	-0.22	-0.34	0.65	-0.26		-0.68	-0.6	0.3	-0.67	0.59	-0.17	-0.66	-0.19	-0.53	0.47
Current Deferred Revenue	0.2	0.13	0.16	0.14	0.19	0.17	0.23	0.05	-0.32	0.2	-0.1	0.28	0.21	-0.55	0.27	-0.68		0.18	0.26	0.54	-0.42	0.29	0.46	0.3	0.46	-0.22
Treasury Stock	0.21	0.19	0.12	0.25	0.08	0.18	0.22	0.2	0.07	-0.07	0.13	0.19	0.12	-0.22	0.2	-0.6	0.18		-0.46	0.39	-0.79	0.09	0.36	0.14	0.34	-0.29
Net Tangible Assets	-0.18	0.08	-0.07	-0.33	0.03	0.16	-0.21	-0.15	-0.12	0.06	-0.12	-0.24	0.17	0.07	-0.12	0.3	0.26	-0.46		0.08	0.17	-0.06	0.19	0.0	0.14	-0.2
Long Term Investments	0.62	0.79	0.51	0.0	0.63	0.28	0.58	0.6	0.32	0.36	0.55	0.57	0.7	-0.04	0.71	-0.67	0.54	0.39	0.08		-0.71	0.53	0.9	0.49	0.87	-0.59
Short Long Term Debt	-0.51	-0.39	-0.41	-0.43	-0.47	-0.15	-0.56	-0.51	-0.43	-0.24	-0.48	-0.44	-0.19	0.01	-0.5	0.59	-0.42	-0.79	0.17	-0.71		-0.26	-0.63	-0.29	-0.56	0.41
Long Term Debt Total	0.68	0.62	0.77	-0.19	0.59	-0.12	0.63	0.57	0.12	0.73	0.51	0.77	0.57	0.4	0.77	-0.17	0.29	0.09	-0.06	0.53	-0.26		0.29	0.64	0.61	0.09
Capital Surpluse	0.41	0.71	0.28	-0.15	0.46	0.27	0.37	0.43	0.34	0.14	0.4	0.31	0.64	-0.12	0.48	-0.66	0.46	0.36	0.19	0.9	-0.63	0.29		0.37	0.76	-0.72
Net Invested Capital	0.58	0.51	0.63	-0.14	0.53	-0.18	0.56	0.52	0.18	0.58	0.47	0.58	0.45	0.18	0.6	-0.19	0.3	0.14	0.0	0.49	-0.29	0.64	0.37		0.58	-0.28
Net Working Capital	0.66	0.8	0.63	-0.26	0.68	0.49	0.61	0.68	0.26	0.47	0.55	0.57	0.73	0.08	0.71	-0.53	0.46	0.34	0.14	0.87	-0.56	0.61	0.76	0.58		-0.44
Cash And Equivalents	-0.01	-0.51	0.11	0.21	-0.15	-0.2	0.03	-0.09	-0.17	0.2	-0.17	0.1	-0.47	0.26	-0.07	0.47	-0.22	-0.29	-0.2	-0.59	0.41	0.09	-0.72	-0.28	-0.44

Click cells to compare fundamentals

About GlaxoSmithKline PLC Financial Statements

GlaxoSmithKline PLC investors utilize fundamental indicators, such as Operating Income, to predict how GlaxoSmithKline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

		Last Reported	Projected for Next Year
	Operating Income	4.6 B	4.7 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. Market participants price GlaxoSmithKline higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive GlaxoSmithKline PLC assessment requires weighing all these inputs, though not all factors influence outcomes equally.

Quarterly Earnings Growth

0.232

Dividend Share

0.64

Earnings Share

3.64

Revenue Per Share

15.82

Quarterly Revenue Growth

0.067

Investors evaluate GlaxoSmithKline PLC ADR using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating GlaxoSmithKline PLC's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause GlaxoSmithKline PLC's market price to deviate significantly from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, GlaxoSmithKline PLC's market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

GlaxoSmithKline Operating Income from 2010 to 2026

Latest GlaxoSmithKline PLC's Operating Income Growth Pattern

GlaxoSmithKline Operating Income Regression Statistics

GlaxoSmithKline Operating Income History

Other Fundumenentals of GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC Operating Income component correlations

About GlaxoSmithKline PLC Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY